<DOC>
	<DOCNO>NCT01061788</DOCNO>
	<brief_summary>This open-label , non-randomized , dose escalation phase I biomarker trial triplet regimen AMG 479 , everolimus , panitumumab subject refractory advance solid tumor design assess safety tolerability combination well preliminary efficacy .</brief_summary>
	<brief_title>A Trial AMG 479 , Everolimus ( RAD001 ) Panitumumab Patients With Advanced Cancer - QUILT-3.007</brief_title>
	<detailed_description>The purpose study find safe dose drug AMG 479 everolimus combination panitumumab add . This study consist two part . If enrol Part One study , receive AMG 479 everolimus . If enrol Part Two study , receive AMG 479 , everolimus , panitumumab . The study also look drug work body , see effect cancer . The study two part : The first part define MTD/RPTD doublet combination AMG 479 + everolimus use standard 3-6 subject per dose level . Since agent know well tolerated monotherapy , start full dose AMG 479 escalate dose everolimus . Once RPTD establish , additional 20 subject add confirm tolerability regimen allow detailed biomarker assessment effect agent alone doublet combination . In biomarker expand cohort , subject start treatment 2 week AMG 479 monotherapy ( single dose AMG 479 ) , follow combination AMG 479 + everolimus day 15 . The second part study assess tolerability triplet therapy , panitumumab add RPTD AMG 479 + everolimus , use standard cohort size 3-6 subject . Finally , recommend phase II dose triplet therapy , 20 subject add expanded safety biomarker cohort . In biomarker expand cohort , 10 subject start treatment two week AMG 479 monotherapy ( single dose AMG 479 ) , 10 subject start treatment two week everolimus monotherapy , subject start triplet combination therapy panitumumab day 15 . Two sustain complete response ( one &gt; 2 year complete response , second &gt; 8 month complete response ) see subject refractory NSCLC ( never smoker ) enrol doublet regimen . Therefore , additional 20 subject NSCLC , never smokers non-smokers ≤ 10 year pack smoking history enrol MTD/RPTD ass safety , tolerability clinical activity specific patient cohort . In cohort , subject start drug cycle 1 , day 1 . ABOUT THE STUDY DRUGS : AMG 479 intravenous ( I.V. , mean vein ) medication make special type human protein call antibody . AMG 479 block activity another protein call IGF-1R important tumor grow . Blocking IGFR-1 activity show slow kill cancer cell laboratory study . AMG 479 currently evaluate clinical research study variety cancer . AMG 479 approve U.S. Food Drug Administration ( FDA ) treatment cancer therefore consider investigational drug . Everolimus pill work block activity substance body know mTOR ( mammalian target rapamycin ) . mTOR important help growth survival normal cancer cell . Blocking mTOR activity show slow kill cancer cell laboratory study . Everolimus currently evaluate clinical research study variety cancer . Everolimus ( AfinitorTM ) approve FDA treatment advance renal cell carcinoma ( kidney cancer ) , subependymal giant cell astrocytoma ( type brain cancer ) , neuroendocrine tumor originate lung gastrointestinal ( GI ) tract , HER2-negative breast cancer . Besides cancer , everolimus also test ability help block rejection solid organ transplant ( liver kidney transplant ) . Everolimus approve purpose Europe United States . Panitumumab another intravenous ( I.V . ) medication make special type human protein call antibody . Panitumumab block activity protein call EGFr also important tumor grow . Blocking EGFr activity show slow kill cancer cell laboratory study . Panitumumab currently evaluate clinical research study variety cancer . Panitumumab ( Vectibix™ ) approve FDA treatment advance colorectal cancer follow 5'FU , oxaliplatin irinotecan chemotherapy regimen .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically and/or cytologically confirm malignant solid tumor refractory standard therapy , standard therapy exist . Disease must measurable RECIST criterion . For NSCLC expand cohort : Only histologically proven adenocarcinoma refractory standard therapy . 2 . Age &gt; 18 year . 3 . Karnofsky Performance Status 60100 . 4 . Life expectancy least 3 month . 5 . Subjects must adequate organ marrow function define : Absolute neutrophil count &gt; /=1,500/μl Platelets &gt; /=100,000/μl Magnesium &gt; /= 1.8 mg/dL Phosphorus &gt; /= 2.3 mg/dL Total bilirubin &lt; /= 1.5 X upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; /=2.5 X ULN , &lt; /=5 X ULN know hepatic metastasis PT/INR ; PTT &lt; /= 1.3 ; &lt; 1.3 X ULN Creatinine clearance &gt; /=40 mL/min/m2 CockroftGault MDRD equation Hemoglobin &gt; 9 g/dL Continuation erythropoietin product permit . Hemoglobin must stable 9 g/dL least 2 week without blood transfusion maintain hemoglobin level . Fasting blood sugar &lt; /= 160 mg/dL Patient may diabetic medication achieve glucose control : Documented fast blood sugar &lt; /= 160 mg/dL Diabetic subject recently glycemic control regimen adjust document fast blood glucose concentration ≤ 160 mg/dL may consider regardless HgbA1c value , per investigator discretion subject consider adequate glycemic function 6 . Ability understand willingness sign write informed consent document . 7 . NSCLS expand cohort : Total 20 never smoker nonsmoker . Never smoker define individual never smoke nonsmoker define individual ≤10 pack year history quit &gt; 15 year 1 . Radiation therapy , hormonal therapy , biologic therapy chemotherapy cancer within 28 day prior day 1 study drug . For NSCLC expand cohort : Palliative radiation therapy ≤14 day day 1 study drug . 2 . Active CNS metastasis . MRI ( CT ) require within 3 month start treatment tumor type know commonly metastasize brain ( i.e . tumor except pancreas , colorectal , ovarian ) patient CNS symptom may represent CNS metastasis . Metastases treat radiotherapy &gt; 2 month prior start protocol therapy asymptomatic ( steroid therapy least 1 month ) may include . Patients must normal stable ( treat , new lesion ) brain imaging ( CT MRI ) within two month prior day 1 study drug . For NSCLC expand cohort : Radiation ≤ 14 day prior day 1 study drug . Subjects must steroids &gt; 14 day prior day 1 study drug anticonvulsant must discontinue . 3 . Inadequately control hypertension ( define systolic blood pressure 140 and/or diastolic blood pressure &gt; 90 mmHg ) . Initiation antihypertensive permit provided adequate control document least 1 week prior day 1 study drug . 4 . Evidence active bleeding diathesis coagulopathy . For NSCLC expand cohort : History `` blood ting '' sputum allow . 5 . No warfarin therapy . Low molecular weight heparin anticoagulation permit provided patient clinically stable anticoagulation least 2 week prior day 1 study drug meet platelet inclusion criterion . No history active GI bleeding major bleed within previous 6 month prior day 1 study drug . 6 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 1 study drug ( 56 day hepatectomy , open thoracotomy , major neurosurgery ) anticipation need major surgical procedure course study . 7 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior day 1 study drug . 8 . Serious , nonhealing wound , ulcer , bone fracture . 9 . Any prior history hypertensive crisis hypertensive encephalopathy . 10 . New York Heart Association ( NYHA ) Grade II great congestive heart failure . 11 . History clinically significant vascular disease , include follow within 6 month prior day 1 study drug : myocardial infarction unstable angina , percutaneous coronary intervention , bypass grafting , ventricular arrhythmia require medication , stroke transient ischemic attack , symptomatic peripheral arterial disease and/or involvement great vessel tumor without vascular grafting . 12 . Chronic treatment systemic steroid another immunosuppressive agent follow exception : Intermittent steroid may use asneeded basis ( e.g . treatment chemotherapyrelated nausea . ) Patients physiologic replacement dos steroid due adrenal insufficiency reason may remain medication . 13 . A known history HIV seropositivity , hepatitis C virus , acute chronic active hepatitis B infection , serious chronic infection require ongoing treatment . 14 . Impairment gastrointestinal function gastrointestinal disease may significantly alter drug absorption ( e.g . inflammatory bowel disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome significant small bowel resection ) . 15 . Patient unwilling unable comply protocol . 16 . Medical need continuous administration drug affect CYP3A4 though use low dose glucocorticoid ( e.g . Dexamethasone &lt; /= 4 mg daily equivalent ) anorexia /or nausea permit . 17 . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis , evidence interstitial lung disease baseline chest CT scan . For NSCLC expand cohort : Scarring previous radiation therapy pneumonia allow . 18 . Patients pregnant and/or lactating exclude study . ( The effect investigational drug develop human fetus know , drug likely embryo fetotoxic . Women childbearing potential men must agree use two form adequate contraception ( hormonal barrier method birth control ; abstinence ) prior day 1 study drug , duration study participation 6 month last dose study drug . Should woman become pregnant suspect pregnant partner participate study , inform treat physician study PI immediately . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . ) 19 . Other concurrent severe and/or uncontrolled medical , psychiatric social condition could compromise safety compliance treatment judge treat physician . Examples include limited : History severely impaired lung function define spirometry DLCO &lt; /= 50 % normal predict value and/or 02 saturation &lt; /= 88 % rest room air . Uncontrolled diabetes mellitus consistent fast blood glucose reading &gt; 160 mg/dL &lt; 50 mg/dL ) . Use diabetic medication permit . Hyperlipidemia ( &gt; CTC Grade 2 : Total Cholesterol &gt; 300400 ; Triglycerides &gt; 2.5 ULN ) . Use lipid lower agent permit . Other : e.g . severe infection , severe malnutrition , ventricular arrhythmia , know active vasculitis cause , tumor invasion major blood vessel , severe chronic liver renal disease , active upper GI tract ulceration . 20 . No immunization attenuate live vaccine within one week study entry study period . 21 Proteinuria screening demonstrate either urine protein : creatinine ( UPC ) ratio great equal 1.0 24hr collection great 1g/24hr screening . 22 NSCLC cohort : Current smoker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
	<keyword>Duke</keyword>
	<keyword>Subjects refractory advance solid tumor</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>